These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21278236)

  • 1. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers.
    Li W; Wang L; Katoh H; Liu R; Zheng P; Liu Y
    Cancer Res; 2011 Mar; 71(6):2162-71. PubMed ID: 21278236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer.
    Yang P; Li Y; Hou J; Wu D; Zeng X; Zeng Z; Zhang J; Xiong Y; Chen L; Yang D; Wan X; Wu Z; Jia L; Liu Q; Lu Q; Zou X; Fang W; Zeng X; Zhou D
    J Biol Chem; 2024 Jun; 300(6):107309. PubMed ID: 38657867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of microRNA-224-3p Hampers Retinoblastoma Progression via Activation of the Hippo-YAP Signaling Pathway by Increasing LATS2.
    Song L; Huang Y; Zhang X; Han S; Hou M; Li H
    Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):32. PubMed ID: 32186675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma.
    Liu K; Ni JD; Li WZ; Pan BQ; Yang YT; Xia Q; Huang J
    Mol Oncol; 2020 Oct; 14(10):2678-2695. PubMed ID: 32634265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
    Guo Y; Cui J; Ji Z; Cheng C; Zhang K; Zhang C; Chu M; Zhao Q; Yu Z; Zhang Y; Fang YX; Gao WQ; Zhu HH
    Oncogene; 2017 Nov; 36(45):6336-6347. PubMed ID: 28745315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.
    Hua K; Jin J; Zhao J; Song J; Song H; Li D; Maskey N; Zhao B; Wu C; Xu H; Fang L
    Int J Oncol; 2016 May; 48(5):1997-2006. PubMed ID: 26934863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
    Huntoon CJ; Nye MD; Geng L; Peterson KL; Flatten KS; Haluska P; Kaufmann SH; Karnitz LM
    Cancer Res; 2010 Nov; 70(21):8642-50. PubMed ID: 20841485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippo pathway and tumoral FOXP3 expression correlate with tumor growth in squamous cell carcinoma of the lung.
    Won KY; Kim HK; Kim GY; Song MJ; Lim SJ
    Pathol Res Pract; 2020 Jul; 216(7):153003. PubMed ID: 32534707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.
    Liu J; Ye L; Li Q; Wu X; Wang B; Ouyang Y; Yuan Z; Li J; Lin C
    J Pathol; 2018 Jan; 244(1):71-83. PubMed ID: 28991374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of tumoral FOXP3 in gastric adenocarcinoma is associated with favorable clinicopathological variables and related with Hippo pathway.
    Suh JH; Won KY; Kim GY; Bae GE; Lim SJ; Sung JY; Park YK; Kim YW; Lee J
    Int J Clin Exp Pathol; 2015; 8(11):14608-18. PubMed ID: 26823784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
    Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
    Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.
    Shi Y; Geng D; Zhang Y; Zhao M; Wang Y; Jiang Y; Yu R; Zhou X
    J Mol Neurosci; 2019 May; 68(1):38-48. PubMed ID: 30771084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.
    Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D
    Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway.
    Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP
    FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.
    Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A
    Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM5 influences Hippo/YAP axis to promote ferroptosis in glioma through regulating WWP2-mediated LATS2 ubiquitination.
    Fan Y; Zou HQ
    Kaohsiung J Med Sci; 2024 Oct; 40(10):890-902. PubMed ID: 39166861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.